ArticleJournal of medical systems2026
MEL-IA: An Interoperable AI System for Multimodal Skin Lesion Classification in Hospital Settings.
Article in Journal of medical systems, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skin cancer represents a growing healthcare challenge, motivating the development of AI sytems that can support lesion assessment while integrating efficiently into clinical workflows. This study presents MEL-IA (MobilE skin Lesion dIAgnosis), an interoperable AI system designed for automated skin lesion classification and full integration with hospital information systems.
methodsThe system combines dermatoscopic images and structured clinical metadata using an EfficientNet-B4 - based multimodal model trained on the ISIC 2019 BCN_20000 and MSK subsets. Internal robustness was assessed through stratified 5-fold cross-validation, and external generalization was evaluated on the independent HAM10000 dataset. Interoperability and operational performance were validated through deployment in a real hospital environment using HL7, DICOM, PACS, and HIS/RIS systems.
resultsWe evaluated internal robustness using stratified five‑fold cross‑validation, with global accuracy of 0.86, macro F1-score of 0.85, and AUC values above 0.97. The external evaluation showed that the model generalizes well under different acquisition conditions, achieving an accuracy of 0.84 and balanced accuracy of 0.65, with sensitivities of 0.60 for melanoma 0.72 for basal cell carcinoma. The multimodal model outperformed the image model baseline across all classes. Technical deployment confirmed full interoperability, > 99% successful study integration, and near real time processing.
conclusionsMEL-IA provides multimodal skin lesion classification capabilities and integrates smoothly into hospital infrastructures based on standards. The results demonstrate technical feasibility, interoperability, and operational viability for deployment within dermatology oriented clinical workflows. Further clinical validation studies are warranted to assess the system's impact on diagnostic decision-making and patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.